Skip to main content
. 2020 Sep 10;5(5):e000753. doi: 10.1136/esmoopen-2020-000753

Figure 2.

Figure 2

Progression free survival (PFS) and overall survival (OS) for the 16 patients that were treated with cetuximab and avelumab in the Cetuximab-AVElumab-Lung trial. (A) Individual patient PFS. (B) Kaplan-Meier estimate for PFS. Median PFS, 2.1 months (95% CI 1.2 to 3.0 months). (C) Individual patient OS. (D) Kaplan-Meier estimate for PFS. Median OS, 6.2 months (95% CI 4.0 to 8.3 months).